magrolimab
6 abstracts
Abstract
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.Org: Stanford Cancer Center, Portuguese Oncology Institute of Porto, Porto, Portugal, The Kinghorn Cancer Centre, CUF Instituto de Oncologia, Macquarie University,
Abstract
A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Rogel Cancer Center, University of Michigan, Huntsman Cancer Center, Oregon Health and Science University, Hospital Virgen del Rocio, Seville, Spain,
Abstract
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.Org: Cairns and Hinterland Hospital and Health Service, Cancer Research South Australia (CRSA), Queen Mary Hospital, Gilead Sciences, Inc., Gilead Sciences Inc,
Abstract
Effects of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy.Org: University of Lincoln,
Abstract
A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML).Org: ImmunoGen, University of Texas MD Anderson Cancer Center, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) IRCCS, Meldola, Italy, Roswell Park Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center,
Abstract
Incidence of drug-induced myelosuppression and associated adverse events (AEs), quality of life (QOL), and medical resource use (MRU) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).Org: Certara Evidence & Access, Gilead Sciences, Inc., Gilead Sciences Europe Ltd,